SG11202000321PA - Cd38 modulating antibody - Google Patents
Cd38 modulating antibodyInfo
- Publication number
- SG11202000321PA SG11202000321PA SG11202000321PA SG11202000321PA SG11202000321PA SG 11202000321P A SG11202000321P A SG 11202000321PA SG 11202000321P A SG11202000321P A SG 11202000321PA SG 11202000321P A SG11202000321P A SG 11202000321PA SG 11202000321P A SG11202000321P A SG 11202000321PA
- Authority
- SG
- Singapore
- Prior art keywords
- stevenage
- tusk
- catalyst
- international
- therapeutics
- Prior art date
Links
- 101150002659 CD38 gene Proteins 0.000 title 1
- 241000581479 Apodichthys Species 0.000 abstract 4
- 239000003054 catalyst Substances 0.000 abstract 4
- 239000002023 wood Substances 0.000 abstract 4
- 241001609030 Brosme brosme Species 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 abstract 1
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 abstract 1
- 241000451147 Lacon Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000968 medical method and process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546322P | 2017-08-16 | 2017-08-16 | |
| US201762582666P | 2017-11-07 | 2017-11-07 | |
| US201762582653P | 2017-11-07 | 2017-11-07 | |
| PCT/EP2018/065237 WO2018224682A1 (en) | 2017-06-08 | 2018-06-08 | Cd38 modulating antibody |
| PCT/EP2018/072271 WO2019034752A1 (en) | 2017-08-16 | 2018-08-16 | CD38 MODULATOR ANTIBODY |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202000321PA true SG11202000321PA (en) | 2020-02-27 |
Family
ID=65361804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202000321PA SG11202000321PA (en) | 2017-08-16 | 2018-08-16 | Cd38 modulating antibody |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12304964B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3668896A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7224338B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102770107B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN111032693B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2018316521B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3073085A1 (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202000321PA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019034752A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020205753B2 (en) | 2019-01-11 | 2025-05-29 | Omeros Corporation | Methods and compositions for treating cancer |
| WO2020185859A1 (en) | 2019-03-12 | 2020-09-17 | Arcus Biosciences, Inc. | Treatment of oncogene-driven cancers |
| EP3947463A4 (en) | 2019-03-29 | 2022-12-21 | Arcus Biosciences, Inc. | CANCER TREATMENT USING AN IDENTIFIED ADENOSINE IMPRESSION |
| CN114437215B (zh) * | 2020-11-05 | 2023-02-07 | 上海麦济生物技术有限公司 | 抗人cd38抗体及其制备方法和用途 |
| CN116136491A (zh) * | 2021-11-18 | 2023-05-19 | 中山康方生物医药有限公司 | 检测抗cd47抗体的装置和检测方法 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020164788A1 (en) | 1994-12-02 | 2002-11-07 | The Wellcome Foundation Limited | Humanized antibodies to CD38 |
| US20030148321A1 (en) | 2001-08-24 | 2003-08-07 | Iris Pecker | Methods and kits for diagnosing and monitoring hematopoietic cancers |
| AU2011202520C1 (en) | 2002-10-17 | 2016-02-18 | Genmab A/S | Human monoclonal antibodies against CD20 |
| US8039218B2 (en) | 2002-11-14 | 2011-10-18 | John Wayne Cancer Institute | Detection of cancer cells in body fluids |
| US9200061B2 (en) | 2004-02-06 | 2015-12-01 | Morpho Sys AG | Generation and profiling of fully human HuCAL gold®-derived therapeutic antibodies specific for human CD3i |
| JP2008504013A (ja) | 2004-02-06 | 2008-02-14 | モルフォシス・アクチェンゲゼルシャフト | 抗ｃｄ３８ヒト抗体及びその用途 |
| US8263746B2 (en) | 2004-02-06 | 2012-09-11 | Morphosys Ag | Anti-CD38 human antibodies and uses thereof |
| NZ586780A (en) | 2005-03-23 | 2012-02-24 | Genmab As | Antibodies against CD38 for treatment of multiple myeloma |
| WO2006113747A2 (en) | 2005-04-19 | 2006-10-26 | Prediction Sciences Llc | Diagnostic markers of breast cancer treatment and progression and methods of use thereof |
| EP2799451A1 (en) | 2005-05-24 | 2014-11-05 | MorphoSys AG | Generation and profiling of fully human HuCAL GOLD®-derived therapeutic antibodies specific for human CD38 |
| KR20150139636A (ko) | 2005-10-12 | 2015-12-11 | 모르포시스 아게 | 인간 ｃｄ38에 특이적인 완전 인간 ｈｕｃａｌ ｇｏｌｄ-유도 치료 항체들의 생성 및 프로파일링 |
| AU2016228249A1 (en) | 2006-09-26 | 2016-10-06 | Genmab A/S | Combination treatment of CD38-expressing tumors |
| AU2013209322A1 (en) | 2006-10-19 | 2013-08-15 | Sanofi-Aventis | Novel anti-cd38 antibodies for the treatment of cancer |
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| KR101552735B1 (ko) | 2006-12-01 | 2015-09-14 | 메다렉스, 엘.엘.시. | 씨디22에 결합하는 인간 항체 및 이의 용도 |
| CN101605906A (zh) | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
| NZ578354A (en) | 2006-12-14 | 2012-01-12 | Medarex Inc | Antibody-partner molecule conjugates that bind cd70 and uses thereof |
| EP2133365B1 (en) | 2006-12-27 | 2017-05-17 | Emory University | Compositions and methods for the treatment of infections and tumors |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| CA2697193C (en) | 2007-09-14 | 2017-06-06 | Adimab, Inc. | Rationally designed, synthetic antibody libraries and uses therefor |
| EP2342220B1 (en) | 2008-10-06 | 2021-05-12 | The University Of British Columbia | Methods and systems for predicting misfolded protein epitopes |
| BR112012006388B1 (pt) | 2009-09-22 | 2022-01-04 | Probiogen Ag | Método para produzir uma molécula, e, método para produzir uma proteína |
| WO2011035433A1 (en) | 2009-09-23 | 2011-03-31 | University Health Network | Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers |
| MX360336B (es) | 2010-07-16 | 2018-10-30 | Adimab Llc Star | Colecciones de anticuerpos. |
| UA112170C2 (uk) | 2010-12-10 | 2016-08-10 | Санофі | Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб |
| JOP20210044A1 (ar) * | 2010-12-30 | 2017-06-16 | Takeda Pharmaceuticals Co | الأجسام المضادة لـ cd38 |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| BR112015021521A2 (pt) | 2013-03-15 | 2017-10-10 | Genentech Inc | anticorpos anti-crth2 e métodos para seu uso |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| SG11201607983YA (en) | 2014-03-28 | 2016-10-28 | Xencor Inc | Bispecific antibodies that bind to cd38 and cd3 |
| MA40894A (fr) | 2014-11-04 | 2017-09-12 | Glenmark Pharmaceuticals Sa | Immunoglobulines hétéro-dimères reciblant des lymphocytes t cd3/cd38 et leurs procédés de production |
| KR20170085131A (ko) | 2014-12-01 | 2017-07-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Dna 항체 작제물 및 그 이용 방법 |
| EP3280443B1 (en) | 2015-04-08 | 2022-08-24 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind cd38 |
| GB201506389D0 (en) | 2015-04-15 | 2015-05-27 | Berkel Patricius H C Van And Howard Philip W | Site-specific antibody-drug conjugates |
| PT3313441T (pt) | 2015-06-24 | 2024-05-07 | Janssen Biotech Inc | Modulação imunitária e tratamento de tumores sólidos com anticorpos que se ligam especificamente a cd38 |
| AU2016332900C1 (en) | 2015-09-29 | 2024-07-04 | Amgen Inc. | ASGR inhibitors |
| RU2761115C1 (ru) | 2015-10-02 | 2021-12-06 | Ф. Хоффманн-Ля Рош Аг | Биспецифические антитела, специфические в отношении костимуляторного tnf-рецептора |
| AU2018280871B2 (en) | 2017-06-08 | 2024-09-26 | Black Belt Therapeutics Ltd | CD38 modulating antibody |
| US11542338B2 (en) * | 2017-08-16 | 2023-01-03 | Black Belt Therapeutics Limited | CD38 modulating antibody |
| EP4036116A4 (en) | 2019-09-27 | 2024-01-24 | Nanjing GenScript Biotech Co., Ltd. | ANTI-VHH DOMAIN ANTIBODIES AND USE THEREOF |
-
2018
- 2018-08-16 CA CA3073085A patent/CA3073085A1/en active Pending
- 2018-08-16 WO PCT/EP2018/072271 patent/WO2019034752A1/en not_active Ceased
- 2018-08-16 EP EP18753198.3A patent/EP3668896A1/en active Pending
- 2018-08-16 CN CN201880051748.0A patent/CN111032693B/zh active Active
- 2018-08-16 AU AU2018316521A patent/AU2018316521B2/en active Active
- 2018-08-16 JP JP2020508326A patent/JP7224338B2/ja active Active
- 2018-08-16 SG SG11202000321PA patent/SG11202000321PA/en unknown
- 2018-08-16 KR KR1020207003075A patent/KR102770107B1/ko active Active
-
2022
- 2022-11-30 US US18/060,135 patent/US12304964B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN111032693B (zh) | 2023-09-26 |
| EP3668896A1 (en) | 2020-06-24 |
| WO2019034752A1 (en) | 2019-02-21 |
| JP2020531003A (ja) | 2020-11-05 |
| CN111032693A (zh) | 2020-04-17 |
| KR20200036860A (ko) | 2020-04-07 |
| JP7224338B2 (ja) | 2023-02-17 |
| NZ761020A (en) | 2025-03-28 |
| KR102770107B1 (ko) | 2025-02-20 |
| AU2018316521B2 (en) | 2025-01-30 |
| US20230089373A1 (en) | 2023-03-23 |
| US12304964B2 (en) | 2025-05-20 |
| CA3073085A1 (en) | 2019-02-21 |
| AU2018316521A1 (en) | 2020-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202000484TA (en) | Cd38 antibody | |
| SG11202000321PA (en) | Cd38 modulating antibody | |
| SG11201908578YA (en) | Fc-optimized anti-cd25 for tumour specific cell depletion | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201903857UA (en) | Antibodies to pd-1 and uses thereof | |
| SG11201803956UA (en) | Anti-dr5 antibodies and methods of use thereof | |
| SG11201907848YA (en) | Antibodies binding to vista at acidic ph | |
| SG11201903454VA (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| SG11201907753TA (en) | Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof | |
| SG11201907299XA (en) | Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201907855QA (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| SG11201908994RA (en) | Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy | |
| SG11201809879WA (en) | Novel antibodies specifically binding to zika virus epitopes and uses thereof | |
| SG11201909322VA (en) | Treatment of asthma with anti-tslp antibody | |
| SG11201909081YA (en) | Anti-ilt4 antibodies and antigen-binding fragments | |
| SG11201907889YA (en) | Glycan-interacting compounds and methods of use | |
| SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
| SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
| SG11201807187XA (en) | Binding members to pd-l1 | |
| SG11201908056QA (en) | Anti-par2 antibodies and uses thereof | |
| SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
| SG11201906853QA (en) | Anti-rsv monoclonal antibody formulation | |
| SG11201810420YA (en) | Antibodies to alpha-synuclein and uses thereof |